Roger Harrison to Annexin A5
This is a "connection" page, showing publications Roger Harrison has written about Annexin A5.
Connection Strength
3.632
-
Anionic phospholipid expression as a molecular target in Listeria monocytogenes and Escherichia coli. Int J Antimicrob Agents. 2020 Dec; 56(6):106183.
Score: 0.689
-
Annexin-directed ß-glucuronidase for the targeted treatment of solid tumors. Protein Eng Des Sel. 2017 Feb; 30(2):85-94.
Score: 0.529
-
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer. Pancreas. 2015 Aug; 44(6):945-52.
Score: 0.481
-
Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy. PLoS One. 2013; 8(10):e76403.
Score: 0.423
-
Antitumor activity of an enzyme prodrug therapy targeted to the breast tumor vasculature. Cancer Invest. 2013 Oct; 31(8):505-10.
Score: 0.423
-
Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine. Cancer Lett. 2011 Aug 01; 307(1):53-61.
Score: 0.358
-
Annexin A5 as a targeting agent for cancer treatment. Cancer Lett. 2022 10 28; 547:215857.
Score: 0.195
-
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
Score: 0.144
-
Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide. Mol Cancer Ther. 2017 09; 16(9):1855-1865.
Score: 0.136
-
Targeting single-walled carbon nanotubes for the treatment of breast cancer using photothermal therapy. Nanotechnology. 2013 Sep 20; 24(37):375104.
Score: 0.105
-
Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature. Cancer Lett. 2011 Feb 28; 301(2):177-84.
Score: 0.087
-
A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties. Blood. 2006 Feb 01; 107(3):980-6.
Score: 0.061